title: Emergency lung biopsy: friend or foe of the immunosuppressed child?
abstract: An acute pneumonic process in an immunosuppressed child poses a diagnostic and therapeutic challenge. These patients tolerate infection poorly. An open lung biopsy may provide prompt diagnosis. Nevertheless, a beneficial change in therapy that results in survival does not necessarily follow. Fifty-six immunosuppressed children with acute respiratory symptoms and interstitial pulmonary infiltrates underwent lung biopsy from 1974 to 1985. The most common underlying diagnosis was acute lymphocytic leukemia (60%). A specific etiology was determined in 46 (82%). Operative morbidity in 52% included prolonged intubation, recurrent pneumothorax, and hemorrhage. Overall, mortality was 34%. Those patients with solid tumor and those who required postoperative ventilation had a statistically significant higher mortality than all others. We defined biopsy "patient benefit" as follows: (1) the biopsy yielded an etiology for which a change of treatment was required; and (2) the child survived this acute illness. Despite the successful diagnostic results of this procedure, only 13 (23%) of the patients derived clinical benefit. Even though a specific infectious etiology was diagnosed in 39 (69%) patients only ten (18%) of these improved and survived after an appropriate change in therapy. Eight of these had Pneumocystis carinii. One survivor benefited from the treatment of documented radiation pneumonitis. Another was successfully treated for graft v host reaction but this diagnosis also was made by skin biopsy. One half of the biopsies were performed very early in the course of the illness, specifically to exclude Pneumocystis carinii of which we saw a peak incidence in 1978 to 1979.(ABSTRACT TRUNCATED AT 250 WORDS)
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001706:Biopsy / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D004338:Drug Combinations / Q000627:therapeutic use; D004630:Emergencies; D006801:Humans; D007108:Immune Tolerance; D007223:Infant; D007945:Leukemia, Lymphoid / Q000150:complications; D008168:Lung / Q000473:pathology*; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000188:drug therapy; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis; D011658:Pulmonary Fibrosis / Q000175:diagnosis* / Q000188:drug therapy; D012189:Retrospective Studies; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
chemical_list: D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole